Abstract: Methods, assays, and compositions for identifying molecular subtypes of metastatic cancer are disclosed. Methods include determining expression levels of genes and/or miRNAs in a sample of metastatic tissue and identifying the molecular subtype of the metastasis based on the determined expression levels using a neural network-based classifier. Methods may further include providing a prognosis and making treatment decision based on the molecular subtype of the metastasis.

Abstract: Aspects of the disclosure include analysis methods and systems useful in, for example, determining protein-protein interaction, characterizing emergent biological function, and discovery of novel protein function. Aspects include generating a spectral matrix representing variation of genetic elements based at least in part on singular value decomposition (SVD) of a first matrix comprising entries representing a number of times each of a genetic element appears in each of a detectable proteome. Biological information contained in one or more cells of the spectral matrix may be quantified to obtain statistical interactions between the genetic elements. The obtained statistical interactions may be correlated with benchmarked biological interactions. Accordingly, a protein-protein interaction may be classified using correlations between the statistical interactions and the benchmarked biological interactions.

Abstract: A method of radiating a plurality of masses in a patient is provided, including receiving a three-dimensional model of the patient, the model including respective locations of a plurality of OARs, receiving a set of locations in the model corresponding to the masses, respective prescribed radiation dosages for the masses, and respective radiation limits for the OARs. The method includes computing a candidate set of beams having respective beam paths that travel through at least one of the masses. The method includes scoring the candidate set of beams based on respective dosages provided to the masses, respective dosages provided to the OARs, and beams in a set of selected beams for treatment, adding a best-scoring beam among the candidate set of beams to the set of selected beams, and radiating the masses using the set of selected beams.

Abstract: Provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, in which R1, R2, R3, R4, R5, X1, X2, and n are described herein. Also provided is a method of treating an estrogen-mediated disease requiring inhibition of estrogen receptor alpha (ER-alpha), such as cancer, in a subject or inhibiting ER-alpha in a cell with the compound of formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: One aspect of the present invention describes materials and methods of quantitatively measuring the density or percent occupancy of DNA binding proteins such as histones, histone variants, histone post translational modifications and transcription factors in chromatin at given DNA loci. One embodiment measures a factor's average quantity at specific gene loci, and controls for a number of pitfalls concerning antibody quality and handling issues. Other embodiments include calibrating and quantifying chromatin immunoprecipitation assays, assessing an affinity reagent specificity, as well as required reagents and their formulation in kits. Another embodiment allows for the diagnosis of a condition or disease by measuring the density of a histone modification at a genomic locus.

Abstract: Disclosed herein are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs to treat apicomplexan parasite related disorders, and biomarkers to identify disease due to the parasite and its response to treatment.

Abstract: A device, system, and method determines a reading environment by synthesizing downstream needs. The method at a workflow server includes receiving a request from a physician device utilized by a referring physician, the request directed to performing an imaging procedure. The method includes determining at least one normalized need from the request, the normalized need corresponding to the referring physician. The method includes generating information to be included in a reading environment based on the at least one normalized need, the information assisting an image interpreter in interpreting the imaging procedure.

Abstract: The present disclosure describes various methods, systems, and storage medium for engineering fast bias-preserving gates on stabilized cat qubits. One method for performing a quantum operation on a qubit using a noise-bias-preserving (NBP) quantum gate includes obtaining and stabilizing the qubit; determining a type of the NBP quantum gate associated with the quantum operation, according to type of the NBP quantum gate, the quantum operation on the qubit to obtain a modified qubit, the quantum operation comprising a base gate drive and a counterdiabatic (CD) control drive. Another method for stabilizing a qubit for quantum storage includes obtaining a qubit; in response to the qubit being in an idle state, applying a two-photon dissipation operation on the qubit to stabilize the qubit, the two-photon dissipation operation corresponding to a two-photon drive.

Abstract: A nanoparticle delivery system designed for sustained delivery of microRNA-150 (miR-150) to FLT3-overexpressing acute myeloid leukemia (AML) cells, the delivery system comprising poly(amidoamine) (PAMAM) dendrimers complexed with miR-150, wherein at least one dendrimer is surface-functionalized with a ligand specific for FLT3 receptor, and methods for treating AML characterized by FLT3-overexpression are provided.

Abstract: Provided herein are compositions and methods for the treatment of cancer by inhibition of ?-catenin or a ?-catenin pathway. In particular, inhibitors of ?-catenin and/or the Wnt/?-catenin signaling pathway are employed prevent or reverse evasion of immune response or immunotherapy by cancers.

Abstract: Described herein is a method for evaluating a subject comprising detecting genetic mutation(s) in the DNA sequence of one or more oral cavity squamous cell carcinoma (OCSCC) biomarker(s) in a biological sample from the subject comprising DNA, wherein the OCSCC biomarker(s) comprise TP53, CDKN2A, FAT1, CASP8, NOTCH1, PIK3CA, and/or ERAS.

Abstract: Embodiments concern methods and composition related to anergic T-cells in patients, such as cancer patients.

Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant.

Abstract: The methods and compositions described herein address the need in the art by providing peptides and polypeptides comprising a growth factor binding domain. In some embodiments, the peptides have an amino acid sequence that is at least 80% identical to one of SEQ ID NOS:1-7, 13-15, 49-50, or 66-70, or a fragment thereof; wherein the peptide is less than 300 amino acids in length.

Abstract: Methods and systems for computationally processing data with a multi-layer convolutional neural network (CNN) having an input and output layer, and one or more intermediate layers are described. Input data represented in a form of evaluations of continuous functions on a sphere may be received at a computing device and input to the input layer. The input layer may compute outputs as covariant Fourier space activations by transforming the continuous functions into spherical harmonic expansions. The output activations from the input layer may be processed sequentially through each of the intermediate layers. Each, intermediate layer may apply Ciebsch-Gordan transforms to compute respective covariant Fourier space activations as input to an immediately next layer, without computing any intermediate inverse Fourier transforms or forward Fourier transforms.

Abstract: Technologies for tuning a resistance of tunnel junctions such as Josephson junctions are disclosed. In the illustrative embodiment, a Josephson junction is heated to 85 Celsius, and an electric field is applied to the Josephson junction. The heat and the electric field cause the resistance of the Josephson junction to increase. Monitoring the Josephson junction during the application of the electric field allows for the resistance of the Josephson junction to be adjusted to a particular value.

Abstract: Stable, macroscopic single-crystal chiral liquid crystal compositions are described. The compositions include a single-crystal chiral liquid crystal material on a patterned surface. The patterned surface seeds a particular crystallographic orientation at the substrate-liquid crystal interface. Also described are methods of forming the single-crystal chiral liquid crystal compositions.

Abstract: Microfluidic devices, systems, and methods.

Abstract: A proximity dependent split T7 RNAP (RNA polymerase) sensor using continuous molecular evolution is described. The versatility of the platform is described by creating robust light and small molecule-responsive genetic sensors. The activity-responsive RNAP platform dramatically simplifies and expands genetic circuit creation, and opens new opportunities in protein engineering, synthetic biology, and bioengineering.

Abstract: Aspects of the present disclosure relate to polypeptides that specifically bind to a SARS-CoV-2 spike protein, and to methods of use for treatment, prevention, and diagnosis of a SARS-CoV-2 infection. Certain aspects are directed to antibodies and fragments thereof, including Fabs, configured to bind to various epitopes within the receptor binding domain (RBD) of a SARS-CoV-2 spike protein. Compositions, kits, and methods for detection of SARS-CoV-2 are also disclosed.